Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1134853 | 0.98 | F10 (0.47) | F10SLC6A4SLC6A3PTGS2CYP1A2 | |
| SCHEMBL1039296 | 0.82 | ALDH1A1 (0.50) | TDP1L3MBTL1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL1038045 | 0.81 | LMNA (0.50) | CYP1A2TDP1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL27976354 | 0.81 | CYP1A2 (0.46) | F10SLC6A4SLC6A3PTGS2CYP1A2 | |
| SCHEMBL23496291 | 0.80 | ALDH1A1 (0.48) | TDP1L3MBTL1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL29413720 | 0.80 | ALDH1A1 (0.48) | TDP1L3MBTL1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL1680278 | 0.80 | ALDH1A1 (0.43) | PTGS2TDP1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL6161641 | 0.79 | STAT3 (0.48) | SLC6A4SLC6A3PTGS2TDP1L3MBTL1 | |
| SCHEMBL18238945 | 0.79 | ABL1 (0.50) | F10TDP1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL3785560 | 0.79 | TDP1 (0.44) | TDP1L3MBTL1SMN1; SMN2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | claimed |
| US-20110251389-A1 | Process For Making N-(Diphenylmethyl)piperazines | ZHU JIE | 2011-10-13 | — | — | US | disclosed |
| US-7989623-B2 | Process for making n-(diphenylmethyl)piperazines | SYNTHON BV (NL) | 2011-08-02 | — | — | US | disclosed |
| CN-102046612-A | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LTD | 2011-05-04 | — | — | CN | disclosed |
| EP-2307392-A2 | PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN | Cipla Limited (IN) | 2011-04-13 | — | — | EP | disclosed |
| EP-2062881-B1 | Process for making N-(diphenylmethyl)piperazines | SYNTHON BV (NL) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009147389-A2 | PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN | CIPLA LIMITED (IN) | 2009-12-10 | — | — | WO | disclosed |
| US-20090143582-A1 | Process for making n-(diphenylmethyl)piperazines | SYNTHON BV (NL) | 2009-06-04 | — | — | US | disclosed |
| WO-2009065622-A1 | PROCESS FOR MAKING N-(DIPHENYLMETHYL)PIPERAZINES | SYNTHON B.V. (NL) | 2009-05-28 | — | — | WO | disclosed |
| EP-2062881-A1 | Process for making N-(diphenylmethyl)piperazines | Synthon B.V. (NL) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009057133-A2 | A PROCESS FOR THE SYNTHESIS OF 2-[2-[4-[(4-CHLOROPHENYL)PHENYL METHYL]-1-PIPERAZINYL] ETHOXY ACETIC ACID | GLENMARK GENERICS LIMITED (IN) | 2009-05-07 | — | — | WO | disclosed |
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251389-A1 | Process For Making N-(Diphenylmethyl)piperazines | CYP51A1, CYP3A5, CYP4Z1 | F10 4819/4885SLC6A4 795/4885SLC6A3 2826/4885 |
| US-20090143582-A1 | Process for making n-(diphenylmethyl)piperazines | CYP51A1, CYP3A5, CYP4Z1 | F10 4819/4885SLC6A4 795/4885SLC6A3 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.